Wiland P

ORCID: 0000-0001-9999-0267 · 2 papers in corpus
2020
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy ·doi:10.1007/s40259-020-00447-6

BackgroundSandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar with similar efficacy and comparable safety and immunogenicity to reference adalimumab (ref-ADL) as confirmed by analytical, pharmacokinetic and confirmatory…

other 2010
Does the KIR2DS5 gene protect from some human diseases?
PloS one ·doi:10.1371/journal.pone.0012381

BACKGROUND: KIR2DS5 gene encodes an activating natural killer cell receptor whose ligand is not known. It was recently reported to affect the outcome of hematopoietic stem cell transplantation. METHODOLOGY/PRINCIPAL FINDINGS: In our studie…